<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015765</url>
  </required_header>
  <id_info>
    <org_study_id>h-APC EMR hybrid study</org_study_id>
    <nct_id>NCT04015765</nct_id>
  </id_info>
  <brief_title>Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence</brief_title>
  <acronym>h-APC EMR</acronym>
  <official_title>Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erbe Elektromedizin GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr John levenick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Alessandro Repici</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic Mucosal Resection (EMR) is the current standard for effective endoscopic resection
      of such colon adenomas. If resection is possible in one piece (so called &quot;en bloc&quot; resection)
      then recurrence rates are low. However, most non-pedunculated polyps &gt;2 cm are removed in
      pieces (&quot;piece-meal&quot; resection) which leads to disease recurrence rates between 12-30%. In
      the March 2019 issue of Gastroenterology Bourke et al. presented that post EMR ablation of
      the resection margins using soft coagulation with the tip of a resection snare reduces
      adenoma recurrence to 5% compared to 21% recurrence found in the control group. Hybrid Argon
      Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for
      submucosal saline injection using a high-pressure water jet. The technique allows to lift
      dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline
      injection and then to ablate larger areas more thoroughly and with a higher energy setting,
      with a low risk for side effects or complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate adenoma recurrence rate</measure>
    <time_frame>3-6 months after the index h-APC and EMR procedure</time_frame>
    <description>The primary aim of the study is to evaluate adenoma recurrence rate after EMR and h-APC margin ablation at the first follow-up colonoscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate complete adenoma eradication rates</measure>
    <time_frame>Within 1 year after the inder EMR</time_frame>
    <description>The secondary aims of the study are to evaluate complete adenoma eradication rates within 1 year after the index EMR when using EMR with margin ablation and ablating all recurrence found at the first follow up colonoscopy with h-APC.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Polyp of Colon</condition>
  <arm_group>
    <arm_group_label>Group treatment h-APC and EMR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard endoscopic mucosal resection (EMR) technique will be used for primary removal of all polyps. Submucosal injection will be used to lift the polyp from the muscularis propria. Injection is used as per the current standard of care using a contrast agent and a lifting agent (e.g. NaCl 0.9% or Voluven). Snare electrocautery resection will be facilitated until complete visible removal of the complete polyp. Electrocautery snare technique is facilitated using standard microprocessor controlled electrocautery (e.g. ERBE VIO Endocut 3-1-6). Ablation of the margin after visibly complete removal of the polyp is routinely applied. For thermal ablation hybrid APC (Erbe Hybrid APC) will be applied using standard settings on the margin and resection base. Once resection and thermal ablation is considered complete the mucosal defect can be closed with clips or another preventative measure applied to reduce the risk for post-polypectomy bleeding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hybrid Argon Plasma Coagulation and EMR procedure</intervention_name>
    <description>Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications</description>
    <arm_group_label>Group treatment h-APC and EMR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Ethnicity and race; Patient referred for endoscopic resection of a 20-50 mm colon
             non-pedunculated colorectal polyp; Written informed consent

        Exclusion Criteria:

          -  Patients with known (biopsy proven) invasive carcinoma in a potential study polyp;
             Previous partial EMR; Pedunculated polyps (as defined by Paris Classification type Ip
             or Isp); Patients with ulcerated depressed lesions (as defined by Paris Classification
             type III); Patients with inflammatory bowel disease; Patients who are receiving an
             emergency colonoscopy; Poor general health (ASA class&gt;3); Patients with coagulopathy
             with an elevated INR ≥1.5, or platelets &lt;50; Poor bowel preparation; Target sign or
             perforation during initial EMR; Need for ESD for complete resection prior to APC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel von Renteln, MD</last_name>
    <phone>5148908000</phone>
    <phone_ext>30912</phone_ext>
    <email>danielrenteln@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Merly</last_name>
    <phone>5148908000</phone>
    <phone_ext>30916</phone_ext>
    <email>louise.merly.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel von Renteln, MD</last_name>
      <phone>5148908000</phone>
      <phone_ext>30912</phone_ext>
      <email>danielrenteln@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Louise Merly</last_name>
      <phone>5148908000</phone>
      <phone_ext>30916</phone_ext>
      <email>louise.merly.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

